Company Filing History:
Years Active: 2023
Introduction
Daniel Leventhal is an accomplished inventor based in Medford, MA, specializing in the field of immunotherapy. With a focus on T cell receptors, he has made significant contributions to medical science aimed at treating diseases such as cancer. His innovative work is crucial in enhancing treatment methodologies, showcasing the power of targeted immunotherapies.
Latest Patents
Daniel Leventhal holds a patent for "T cell receptors that bind to NY-ESO-1 and methods of use thereof." This patent encompasses T cell receptors capable of binding to NY-ESO-1, along with associated cells and pharmaceutical compositions. It also details nucleic acids encoding these receptors, expression vectors, and host cells used for synthesizing them. Importantly, the patent outlines various methods for utilizing these TCRs in treating subjects, marking a notable advancement in therapeutic options available for patients.
Career Highlights
Currently, Daniel is employed at Mink Therapeutics, Inc., where he collaborates with fellow talented professionals in the biopharmaceutical field. His work emphasizes the development of innovative therapies that leverage the immune system's natural capabilities to combat diseases more effectively.
Collaborations
At Mink Therapeutics, Inc., Daniel works alongside distinguished colleagues such as Marc A Van Dijk and Volker Seibert. Together, they aim to drive advancements in therapeutic strategies and contribute significantly to the burgeoning field of immunotherapy that has the potential to save countless lives.
Conclusion
Daniel Leventhal’s pioneering work in the development of T cell receptors highlights his role as a key inventor in the realm of immunotherapy. His contributions, particularly through his patent, underscore the importance of innovation in medicine, demonstrating a pathway toward more effective treatments for diseases like cancer. As he continues to work with his team at Mink Therapeutics, the potential for further groundbreaking discoveries is promising.